Modus Therapeutics Holding AB (publ) (MODTX) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Then I say welcome to today's presentation from Modus Therapeutics, which has presented its part-time report for the third quarter of 2024. And with me to comment on it I have, as usual, the company's CEO, John Öd. John, we are both a bit crass today. You can hear my voice here and it may disappear, so I have a reservation to get through this, but otherwise you take over, quite simply. Yes, in that regard, my voice holds. As I said, we both have to lead each other, quite simply. But please comment briefly on the quarter. There are several milestones that have been achieved. I thought the most interesting milestone is the CKD study that is now approved in Italy. I thought we could start there. Yes, this is for those who may not be familiar with how it works, but we discussed last quarter how our applications had gone in and what happens then is that you work with I am privileged to work with a team of experts who have a very long experience in their areas. The chemistry and substance area, the clinical operations area or the operative clinical area and so on, regulatory, strategic area. And there you go together and work to answer the questions that it is the work of the authority to have. And all authorities have a little different angles, a little different work tradition. And as we also tried to explain at the last quarter's report, there is also a new system called CETIS, which is completely, one could say, datorized, where things are a little more square and that also gives greater degrees of freedom in terms of time. So we have worked very intensively in this system and the success that can be achieved in this work is just to get approved as we have now. And what we are very happy about is that it opens up for us to focus on starting to deliver the study, to sta...